Craig J Currie

List of Publications by Year
in descending order

67 papers	3,279 citations	257450 24 h-index	144013 57 g-index
69 all docs	69 docs citations	69 times ranked	4586 citing authors

#	ARTICLE	IF	CITATIONS
1	Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet, The, 2010, 375, 481-489.	13.7	770
2	Mortality After Incident Cancer in People With and Without Type 2 Diabetes. Diabetes Care, 2012, 35, 299-304.	8.6	381
3	Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research and Opinion, 2006, 22, 1523-1534.	1.9	236
4	Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Current Medical Research and Opinion, 2005, 21, 1477-1483.	1.9	201
5	The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes. Diabetes Care, 2012, 35, 1279-1284.	8.6	194
6	Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 668-677.	3.6	167
7	Antibiotic treatment failure in four common infections in UK primary care 1991-2012: longitudinal analysis. BMJ, The, 2014, 349, g5493-g5493.	6.0	97
8	Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013. Diabetes Care, 2013, 36, S155-S161.	8.6	86
9	What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4605-4612.	3.6	79
10	The Routine Collation of Health Outcomes Data from Hospital Treated Subjects in the Health Outcomes Data Repository (HODaR): Descriptive Analysis from the First 20,000 Subjects. Value in Health, 2005, 8, 581-590.	0.3	77
11	Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Current Medical Research and Opinion, 2006, 22, 121-129.	1.9	69
12	The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child and Adolescent Psychiatry and Mental Health, 2013, 7, 34.	2.5	60
13	Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology, 2014, 53, 186-194.	1.9	56
14	The impact of the overactive bladder on health-related utility and quality of life. BJU International, 2006, 97, 1267-1272.	2.5	54
15	Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin. BMJ Open, 2011, 1, e000258-e000258.	1.9	50
16	The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximinâ€Î±. Liver International, 2016, 36, 1295-1303.	3.9	46
17	External Validation of the UKPDS Risk Engine in Incident Type 2 Diabetes: A Need for New Type 2 Diabetesâ€"Specific Risk Equations. Diabetes Care, 2014, 37, 537-545.	8.6	42
18	Epidemiology and Costs of Acute Hospital Care for Cerebrovascular Disease in Diabetic and Nondiabetic Populations. Stroke, 1997, 28, 1142-1146.	2.0	42

#	ARTICLE	IF	CITATIONS
19	The impact of treatment non-compliance on mortality in people with type 1 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 219-223.	2.3	30
20	The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Current Medical Research and Opinion, 2007, 23, S33-S39.	1.9	29
21	The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Current Medical Research and Opinion, 2007, 23, S41-S48.	1.9	28
22	Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Current Medical Research and Opinion, 2007, 23, S21-S31.	1.9	27
23	Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190‰µg intravitreal implant in people with diabetic macular edema. Current Medical Research and Opinion, 2017, 33, 5-17.	1.9	27
24	Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Current Medical Research and Opinion, 2007, 23, S7-S19.	1.9	26
25	Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status. PLoS ONE, 2019, 14, e0221044.	2.5	24
26	Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. PLoS ONE, 2016, 11, e0153594.	2.5	24
27	Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. BMJ Open, 2017, 7, e013398.	1.9	22
28	Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population. Current Medical Research and Opinion, 2005, 21, 1905-1913.	1.9	21
29	The relationship between self‐reported severe pain and measures of socio‐economic disadvantage. European Journal of Pain, 2011, 15, 1107-1111.	2.8	21
30	The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications. Diabetes Research and Clinical Practice, 2005, 67, 144-151.	2.8	20
31	Impact of treatment with pioglitazone on stroke outcomes: A real‐world database analysis. Diabetes, Obesity and Metabolism, 2018, 20, 2140-2147.	4.4	18
32	Endogenous hyperinsulinaemia and exogenous insulin: A common theme between atherosclerosis, increased cancer risk and other morbidities. Atherosclerosis, 2012, 222, 26-28.	0.8	16
33	The Demand for Hospital Services for Patients with Epilepsy. Epilepsia, 1998, 39, 537-544.	5.1	14
34	Estimation of health-related utility (EQ-5D index) in subjects with seasonal allergic rhinoconjunctivitis to evaluate health gain associated with sublingual grass allergen immunotherapy. Health and Quality of Life Outcomes, 2014, 12, 99.	2.4	14
35	Evaluation of the clinical effectiveness of fluocinolone acetonide 190‰µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Current Medical Research and Opinion, 2017, 33, 19-31.	1.9	14
36	Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190‰µg intravitreal implant for diabetic macular edema. Current Medical Research and Opinion, 2017, 33, 33-43.	1.9	14

#	Article	IF	Citations
37	Cough presentation in primary care and the identification of chronic cough: a need for diagnostic clarity?. Current Medical Research and Opinion, 2020, 36, 139-150.	1.9	14
38	Natural History of Patients Taking Rifaximin-Î± for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. Clinical Therapeutics, 2016, 38, 1081-1089.e4.	2.5	13
39	Evaluation of the epidemiology of peanut allergy in the United Kingdom. Expert Review of Clinical Immunology, 2019, 15, 1333-1339.	3.0	12
40	An overview and commentary on retrospective, continuous glucose monitoring for the optimisation of care for people with diabetes. Current Medical Research and Opinion, 2009, 25, 2389-2400.	1.9	11
41	Hospital Utilization as a Function of Social Deprivation: Diabetes vs Non-Diabetes. , 1997, 14, 589-594.		10
42	Impact of differing glucoseâ€‑lowering regimens on the pattern of association between glucose control and survival. Diabetes, Obesity and Metabolism, 2018, 20, 821-830.	4.4	9
43	Non-Response to Antibiotic Treatment in Adolescents for Four Common Infections in UK Primary Care 1991â€"2012: A Retrospective, Longitudinal Study. Antibiotics, 2016, 5, 25.	3.7	8
44	Health-economic evaluation of fluocinolone acetonide 190â€°Âµg implant in people with diabetic macular edema. Current Medical Research and Opinion, 2017, 33, 45-52.	1.9	8
45	Evaluation of the healthcare resource use and the related financial costs of managing peanut allergy in the United Kingdom. Expert Review of Clinical Immunology, 2019, 15, 889-896.	3.0	8
46	Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Current Medical Research and Opinion, 2019, 35, 1165-1176.	1.9	8
47	Descriptive epidemiology of hospitalisation for psoriasis. Current Medical Research and Opinion, 2008, 24, 3487-3491.	1.9	7
48	A genetic programming approach to development of clinical prediction models: A case study in symptomatic cardiovascular disease. PLoS ONE, 2018, 13, e0202685.	2.5	7
49	Evaluation of the cost-effectiveness of rifaximin-Î± for the management of patients with hepatic encephalopathy in the United Kingdom. Current Medical Research and Opinion, 2018, 34, 2001-2008.	1.9	7
50	The financial burden of treating patients presenting with acute and chronic cough. Current Medical Research and Opinion, 2021, 37, 2175-2184.	1.9	7
51	Do the benefits of analog insulins justify their costs?. Diabetes Management, 2012, 2, 173-175.	0.5	6
52	The effect of withdrawal of rosiglitazone on treatment pathways, diabetes control and patient outcomes: A retrospective cohort study. Journal of Diabetes and Its Complications, 2014, 28, 360-364.	2.3	6
53	Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: AÂRetrospective Study. Diabetes Therapy, 2018, 9, 269-283.	2.5	6
54	The demand and financial cost of hospital care for diabetes mellitus and its related complications. , 1998, 15, 449-451.		5

#	Article	IF	Citations
55	Clinical Effectiveness of Biphasic Insulin Aspart 30:70 Versus Biphasic Human Insulin 30 in UK General Clinical Practice: A Retrospective Database Study. Clinical Therapeutics, 2011, 33, 27-35.	2.5	5
56	Comparative estimated effectiveness of antibiotic classes as initial and secondary treatments of respiratory tract infections: longitudinal analysis of routine data from UK primary care 1991â€"2012. Current Medical Research and Opinion, 2016, 32, 1023-1032.	1.9	5
57	Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema. Current Medical Research and Opinion, 2020, 36, 959-965.	1.9	5
58	Comorbid diseases and conditions in people with HIV in the UK. Current Medical Research and Opinion, 2022, 38, 277-285.	1.9	4
59	The absolute risk of incident type 2 diabetes following exposure to systemic corticosteroids in selected steroidâ€related and phenotypic groups. Diabetes, Obesity and Metabolism, 2022, 24, 2222-2231.	4.4	3
60	Costs of Insulin-dependent Diabetes Mellitus. Diabetic Medicine, 1996, 13, 684-684.	2.3	2
61	Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: <scp>A</scp> retrospective cohort study. Diabetes, Obesity and Metabolism, 2017, 19, 1097-1105.	4.4	2
62	Hospital admissions for severe infections in people with chronic kidney disease in relation to renal disease severity and diabetes status. Endocrinology, Diabetes and Metabolism, 2018, 1, e00029.	2.4	2
63	Comment and Reply on:Relative efficacy/effectiveness and relative costs of treatment with insulin glargine and insulin detemir. Current Medical Research and Opinion, 2007, 23, 1761-1764.	1.9	1
64	Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs. Diabetologia, 2014, 57, 2001-2002.	6.3	1
65	The Model of Mortality with Incident Cirrhosis (MoMIC) and the model of Long-term Outlook of Mortality in Cirrhosis (LOMiC). PLoS ONE, 2019, 14, e0223253.	2.5	1
66	Scientific independence and objectivity: many questions linger about treatment of type 2 diabetes, such as scientific study design, optimal glucose control and the safety of injecting exogenous insulin. Postgraduate Medicine, 2020, 132, 667-675.	2.0	0
67	Cost of dose escalation in people with rheumatoid arthritis treated with tumour necrosis factor inhibitors across Europe. Clinical and Experimental Rheumatology, 2016, 34, 679-84.	0.8	0